ArticleJACC. Advances2025
Noninvasive Screening for Elevated LVEDP and Health Status in Outpatients at Risk for Heart Failure.
Article in JACC. Advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
backgroundHeart failure (HF) is frequently underrecognized in primary care due to nonspecific symptoms, resulting in many patients presenting with severely compromised health status (symptoms, function, and quality of life) at the time of diagnosis.
objectivesThe purpose of this study was to evaluate the diagnostic yield of screening outpatients at risk for HF using a noninvasive assessment of left ventricular end-diastolic pressure (LVEDP) and describe the health status of patients identified with elevated LVEDP.
methodsA convenience sample of adults with diabetes mellitus, chronic kidney disease (CKD), or suspected HF were screened at 3 primary care clinics using the Vivio System to identify patients with LVEDP >18 mm Hg (positive screening). Among patients with a positive screening result, health status was assessed using the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score.
resultsAmong 2,040 screened patients (mean age 74 ± 8 years; 49.8% women; 64.6% with diabetes mellitus; and 34.9% with CKD), 38.5% had an elevated LVEDP. Older patients, women, and those with CKD were more likely to have an elevated LVEDP (P < 0.01 for all). Of 653 KCCQ-OS scores collected (mean 85 ± 20), 31.4% had a KCCQ-OS of 100 (asymptomatic), and 26.5% had a KCCQ-OS <80, consistent with NYHA functional class II-IV.
conclusionsNearly 40% of screened patients with HF risk factors had an elevated LVEDP, with over two-thirds reporting significant health status impairment. Combining the KCCQ with noninvasive LVEDP assessments can identify patients who may require further HF evaluation. Future studies should assess the impact of these strategies on patients' subsequent treatment, health status, and clinical events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.